FSI “SID & GP” and Pharmstrategy, LTD., within the joint program of promoting implementation of the best practices in the russian pharmaceutical industry, will hold an open expert-advisory workshop on the topic: “Risk analysis in elaboration of environmental monitoring programs”
The purpose of the environmental monitoring program is to prove acceptability of the required drug manufacture conditions, to control concentration of contaminating agents (microorganisms and particulate matter) in the manufacturing environment, to be able to detect deviations and possible sources of contamination, as well as to elaborate relevant corrective and preventive actions. The monitoring program shall guarantee immediate feedback allowing for urgent elimination of any problem detected throughout the whole process of manufacture of each product batch/lot.
In terms of manufacture of sterile drugs, GMP guidelines establish rather stringent requirements for organization and implementation of environmental monitoring. Non-conformities related to improper execution of environmental monitoring activities are expected to be classified as major or critical as they undermine sterility/microbial purity of products and, consequently, may have a negative impact on drug safety when administered by a patient.
Taking into account risk management principles integrated into the GMP philosophy, environmental monitoring shall be considered as one of the key objects of risk management embracing the peculiarities of products manufactured, the technology of their manufacture and the equipment used in it. To properly implement risk management principles in terms of environmental monitoring in practice, it is necessary to form respective competences with personnel responsible for this process, including a pool of theoretical knowledge and practical skills in the domain.
The workshop will include the following
- an overview of regulatory requirements for environmental monitoring in connection with risk analysis in pharmaceutical manufacture;
- recommendations on the application of risk analysis methods and tools when elaborating monitoring programs;
- a presentation of the key information in terms of the equipment and materials used in environmental monitoring, as well as planning and reporting about the process;
- a discussion and a detailed analysis of the most frequent non-conformities found during inspections on the environmental monitoring topic;
- an overview of current expectations of the inspectorate in terms of risk analysis application in elaboration of environmental monitoring programs according to EAEU GMP and Russian GMP.
The workshop will feature the following speakers and experts:
Dmitry Sheiman – General Director of PHARMSTRATEGY, LTD. – workshop lead;
Victoriya Gortinskaya – Head of Good Practices Implementation Department of FSI “SID & GP” – joint program moderator;
Anton Avramenko – Head of GMP Methodology and Training Programs Development Department of FSI “SID & GP”, PhD in Pharmacy;
Vladimir Orlov – Line Manager of EAEU Pharmaceutical Inspectorates Cooperation Organization Department of FSI “SID & GP”;
Eugenia Arakcheeva – Assistant to General Director of PHARMSTRATEGY, LTD
- The volume of Indian drugs in the Russian market was $770 mln in 2018
- Mr. Vladislav Shestakov called for taking a quantum leap in GLP
- Interaction points were discussed by SID & GP with EDQM
- The inspection of the foreign pharmaceutical company registering its drug product in Kazakhstan was carried out by the Russian Inspectorate
- 157 license holders out of 189 manufacturing sites have received a GMP-certificate following the procedure of filing an application